MapLight Therapeutics
PublicMapLight Therapeutics is now publicly traded
The data on this page reflects MapLight Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Oct 29, 2025
Last Round
Series D
Jul 28, 2025
Est. Valuation at Exit
$816M
Total Funding Raised
$945.4M
Company Overview
MapLight Therapeutics is a biopharmaceutical company that develops circuit-specific pharmacotherapies for central nervous system disorders using a proprietary platform combining optogenetics, transcriptomics, and spatial biology.
Sector
Biotech
AI Layer
Application
Keywords
MapLight Therapeutics Comparables
Compare MapLight Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neurosterix | 74% | |
| Tortugas Neuroscience | 74% | |
| Amani Therapeutics | 71% |
For institutional investors. Book with your work email.
MapLight Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Oct 29, 2025 | ||||
| Series D | Jul 28, 2025 | ||||
| Series C | Oct 30, 2023 | ||||
| Grant | Aug 4, 2021 | ||||
| Series B | Feb 1, 2021 | ||||
Grant | Nov 30, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
MapLight Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | IPO |
| Avego Management | Series D |
| Forbion | Series D |
| Life Sciences at Goldman Sachs Alternatives | Series D |
| TD Securities | Series C |
| Blue Owl Capital | Series D, Series C, Series A, Series B |
| 5AM Ventures | Series D, Series C, Series A, Series B, Seed |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingAug 13, 2026
MapLight Therapeutics, Inc. announces a $150M private placement financing led by new and existing institutional investors, with closing expected on Aug 14th '26, to advance ML-007C-MA programs and support working capital and other general corporate purposes in California and Massachusetts on Aug 13th '26.
For institutional investors. Book with your work email.
MapLight Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.